Patients with TNBC response to anti-PD-1/PD-L1 therapy, and inhibitors of the MAPK/ERK signaling cascade showed impeding effect on proliferation and clinical potency in diverse cancer entities. The gene discussed is PDCD1; the disease is cancer.